B-cell malignancies

August 23, 2019

FDA Grants Priority Review to Zanubrutinib as Treatment for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review BeiGene‘s application requesting the approval of zanubrutinib for treating people with mantle cell lymphoma who received at least one ... Read more

June 25, 2019

Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma

News

Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b trial ... Read more

January 12, 2018

FDA Clears Voruciclib for Phase 1 Trial as Potential Treatment for Certain B-cell Malignancies

News

The U.S. Food and Drug Administration (FDA) has cleared the way for MEI Pharma to launch a Phase 1 study of voruciclib, its oral CDK9 inhibitor, to treat people with ... Read more

September 19, 2017

UCSD Researchers Awarded $18.3M to Study New Combo Therapy for B-cell Cancers

News

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) has aproved an $18.29 million grant to researchers at the University of California San Diego (UCSD) School ... Read more